The Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively Buys 250,000 Shares

The Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively purchased 250,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was bought at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the completion of the acquisition, the director now owns 616,753 shares of the company’s stock, valued at approximately $104,848.01. The trade was a 68.17 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Brad Hively also recently made the following trade(s):

• On Monday, December 2nd, Brad Hively acquired 50,000 shares of Oncology Institute stock. The stock was bought at an average cost of $0.15 per share, with a total value of $7,500.00.

Oncology Institute Trading Down 4.0 %

Shares of NASDAQ:TOI traded down $0.01 during trading on Monday, reaching $0.16. 1,904,948 shares of the company were exchanged, compared to its average volume of 422,813. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The firm has a market capitalization of $11.75 million, a PE ratio of -0.20 and a beta of 0.60. The business’s fifty day simple moving average is $0.28 and its 200-day simple moving average is $0.39. The Oncology Institute, Inc. has a 12-month low of $0.13 and a 12-month high of $2.50.

Institutional Investors Weigh In On Oncology Institute

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Tiff Advisory Services LLC lifted its holdings in shares of Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock worth $653,000 after buying an additional 995,280 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Oncology Institute by 142.3% in the second quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock valued at $156,000 after acquiring an additional 199,300 shares in the last quarter. Finally, HighTower Advisors LLC lifted its stake in Oncology Institute by 190.8% in the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after acquiring an additional 53,382 shares during the period. 36.86% of the stock is owned by institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.